On the impact of the election on Orion and the pharmaceutical industry in general. Still, with the caveat that the gentleman in question is unpredictable and “anything” is possible.
“According to Vaarala, Donald Trump’s election as president will not necessarily bring much new to the hot topics of the US pharmaceutical market. Drug prices have already been a major topic of discussion there anyway in recent years. Republicans and Democrats share a common understanding that federal drug costs should be reduced.”